Simon Rule

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Nibedita Bandyopadhyay, Martin Dreyling, Mathias Witzens-Harig, 2016, The Lancet.